Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
Rhea-AI Summary
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced on January 5, 2026 the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary and her election to the Board of Directors, effective immediately.
Ms Sharp joined Biodexa as Group Financial Controller in December 2019 and has assumed many CFO responsibilities during her tenure. Her prior roles include Assistant Director of Finance at Hywel Dda University Health Board (over 10,000 staff; budget ~£800 million) and senior finance roles at Chime Communications Group (revenues ~£570 million) from 1999 until early 2018. Stephen Stamp will relinquish his CFO and Company Secretary roles but will remain as Chief Executive Officer.
Positive
- Immediate internal promotion of Fiona Sharp to CFO and company secretary
- Board addition: Fiona Sharp elected to the Board effective immediately
- Internal continuity: Fiona has served at Biodexa since December 2019
- Relevant public-sector finance experience: Hywel Dda budget ~£800m
- Private-sector scale experience: Chime Communications revenues ~£570m
Negative
- Executive role change: Stephen Stamp will relinquish CFO and company secretary roles
- Disclosure inconsistency: contact table still lists Stephen Stamp as CEO, CFO
News Market Reaction – BDRX
On the day this news was published, BDRX gained 2.03%, reflecting a moderate positive market reaction. Argus tracked a trough of -3.2% from its starting point during tracking. This price movement added approximately $32K to the company's valuation, bringing the market cap to $2M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BDRX gained 8.37% while close biotech peers showed mixed moves, with some like QLGN up and others such as GLTO and ENTO down, indicating a stock-specific move rather than a broad sector shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Equity offering | Negative | -24.0% | Dilutive $10 million best‑efforts public offering with warrant coverage. |
| Dec 01 | Clinical milestone | Positive | +2.2% | First European patients enrolled in pivotal Phase 3 Serenta FAP trial. |
| Nov 24 | Clinical milestone | Positive | -1.4% | First European site activated for registrational Phase 3 Serenta trial. |
| Nov 03 | Regulatory/clinical | Positive | -2.4% | EMA CTA approval for Phase 3 Serenta trial and $7B market comment. |
| Oct 06 | Conference activity | Neutral | -1.0% | Announcement of FAP‑focused symposium alongside ongoing Phase 3 program. |
Recent news shows mixed price reactions: financing drew a sharp selloff, while key Phase 3 milestones and events produced modest, often muted moves.
Over the last few months, Biodexa’s trajectory has centered on financing and advancing its eRapa program. A best‑efforts public offering on Dec 18, 2025 led to a -23.99% move, highlighting sensitivity to dilution. In contrast, multiple Phase 3 Serenta trial milestones between Nov 3 and Dec 1, 2025 produced only small price changes, both positive and negative. The current appointment of a new CFO and Company Secretary fits into a period of balance‑sheet rebuilding and late‑stage clinical execution.
Market Pulse Summary
This announcement highlights a leadership transition, with Fiona Sharp promoted to CFO and Company Secretary and joining the Board after several years in expanding finance roles. It follows a period marked by significant financing activity and advancement of a pivotal Phase 3 Serenta trial. Investors may watch how the new CFO steers capital allocation, supports ongoing clinical programs, and manages communication following recent offerings and cash levels reported in late 2025.
AI-generated analysis. Not financial advice.
January 05, 2026
Biodexa Pharmaceuticals PLC
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect.
Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistently broadened her remit to include many of the responsibilities of a CFO. Before joining Biodexa Ms Sharp was Assistant Director of Finance for the Hywel Dda University Health Board, an organization with over 10,000 staff and a budget of approximately
Stephen Stamp will relinquish his roles as Chief Financial Officer and Company Secretary but remain as Chief Executive Officer.
Commenting, Dr Stephen Parker, Chairman of Biodexa, said “In the six years she has been with us, Fiona has made very significant contributions to the financial governance of the Group, sometimes in extremely challenging circumstances. This promotion is well-deserved and the other directors and I are looking forward to working alongside Fiona on the Biodexa Board”.
For more information, please contact:
| Biodexa Pharmaceuticals PLC |
| Stephen Stamp, CEO, CFO |
| Tel: +44 (0)29 20480 180 |
| www.biodexapharma.com |
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.
eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
FAQ
Who was appointed CFO of Biodexa (BDRX) on January 5, 2026?
What roles will Stephen Stamp hold at Biodexa (BDRX) after January 5, 2026?
How long has Fiona Sharp worked at Biodexa (BDRX) prior to becoming CFO?
What prior finance experience does Fiona Sharp have noted by Biodexa (BDRX)?
Is Fiona Sharp joining the Biodexa (BDRX) Board of Directors immediately?
